Why Is Serina Therapeutics Stock Falling In Pre-market?
(RTTNews) - Serina Therapeutics (SER) announced that the FDA has placed a clinical hold on the Investigational New Drug application for SER-252, Serina's lead development program for advanced Parkinsons disease. The FDA has requested additional information related to a commonly used excipient in the formulation.
Serina said it expects to receive the FDA's formal clinical-hold letter within 30 days and will provide an update once it has aligned with the FDA on next steps and timelines.
Shares of Serina Therapeutics are down 8% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.